Taming the Immune Storm: WSU Researcher Awarded $3M NIH Grant to Combat RSV-Induced Lung Damage

By Editorial Staff, Science & Health Desk
September 29, 2026

In a significant breakthrough for respiratory medicine, Washington State University (WSU) researcher Santanu Bose has been awarded a five-year, $3.04 million grant from the National Institutes of Health (NIH). The funding is earmarked for an ambitious project that seeks to unravel the complex biological mechanisms behind how the human immune system, while attempting to fight off respiratory syncytial virus (RSV), inadvertently inflicts severe damage on the lungs.

This research, conducted in collaboration with the Fox Chase Cancer Center in Philadelphia, aims to transition from traditional anti-viral approaches to a more sophisticated "host-directed" strategy. By identifying the specific signaling pathways that turn a protective immune response into a destructive inflammatory force, Dr. Bose and his team hope to pave the way for a new generation of therapeutics capable of mitigating the life-threatening complications of RSV and related respiratory pathogens.

The Double-Edged Sword: Understanding RSV Pathology

Respiratory syncytial virus remains one of the most formidable challenges in global public health. While it often presents as a common cold in healthy adults, it is a leading cause of severe lower respiratory tract infections—including pneumonia and bronchiolitis—in infants, the elderly, and immunocompromised individuals. Beyond the immediate threat of acute infection, early-childhood RSV cases have been clinically linked to a long-term increased risk of chronic respiratory conditions, most notably asthma.

Dr. Santanu Bose, a professor of immunology and infectious diseases at WSU’s College of Veterinary Medicine, describes the body’s reaction to the virus as a "double-edged sword."

"We’re trying to understand why the immune response sometimes goes too far and ends up damaging the lungs by inflammation," Bose explained. "In many ways, the body could eliminate the virus with a regulated inflammatory response, but instead, it responds with excessive inflammation, which ends up harming the host."

The core of the issue lies in a process known as lytic cell death—comprising subtypes called necroptosis and pyroptosis. When RSV infects lung cells, the immune system triggers these pathways to destroy the infected cells. However, when these cells rupture, they release a cascade of inflammatory mediators into the surrounding tissue. This uncontrolled release is what clinicians identify as the primary driver of the lung damage associated with severe viral pneumonia.

Chronology of the Research Initiative

The path to this $3.04 million NIH grant is the result of years of preliminary investigations within Dr. Bose’s laboratory at WSU. The trajectory of this research can be broken down into the following key phases:

Phase I: Identifying the Signaling Pathway (2020–2024)

During the early years of his tenure at WSU, Dr. Bose’s laboratory focused on mapping the cellular signaling events that occur immediately following RSV cellular entry. The team successfully identified a specific "master switch" pathway responsible for triggering lytic cell death. This discovery was critical, as it provided a tangible target for potential therapeutic intervention.

Phase II: Cross-Institutional Collaboration (2025)

Recognizing the complexity of immunological signaling, Dr. Bose initiated a partnership with Sid Balachandran, the director of the Center for Immunology at the Fox Chase Cancer Center. By combining WSU’s expertise in viral pathogenesis with the specialized immunological insights at Fox Chase, the researchers were able to develop a robust hypothesis for the current NIH-funded study.

Phase III: Grant Acquisition and Future Projection (2026–2031)

With the formal announcement of the $3.04 million grant on September 29, 2026, the project is now entering its formal five-year experimental phase. Over the coming half-decade, the team will utilize advanced molecular biology techniques to isolate these inflammatory signals and test the efficacy of novel compounds in blocking the damage-inducing cellular pathways without compromising the body’s ability to clear the virus.

Supporting Data and The Mechanics of Inflammation

To understand the necessity of this research, one must look at the data surrounding respiratory viral infections. Current standards of care for RSV are largely supportive, focusing on oxygen therapy and hydration, as there are limited options to reverse the lung tissue damage once it has begun.

The Role of Lytic Cell Death

When a virus like RSV infects a host cell, the body recognizes viral proteins and initiates a defense. Under normal circumstances, this is a controlled process. However, during an RSV infection, the "lytic" pathways become hyperactive:

• Necroptosis: A programmed form of inflammatory cell death that acts as a "backup" to apoptosis. In the context of the lungs, mass necroptosis leads to a localized "cytokine storm," resulting in the fluid buildup associated with pneumonia.
• Pyroptosis: A highly inflammatory form of programmed cell death that is triggered by the activation of inflammasomes. This process releases massive amounts of IL-1β and other inflammatory cytokines, which recruit more immune cells to the site, creating a cycle of escalating damage.

The WSU project intends to provide the first high-resolution mapping of how these pathways are hijacked by RSV, providing the empirical data needed for pharmaceutical companies to develop host-directed therapeutic agents.

Official Perspectives: Implications for Modern Medicine

The implications of this research extend far beyond RSV. By focusing on the host response rather than just the virus, Dr. Bose is aligning his work with a burgeoning field of "Precision Immunology."

"Often it’s not the virus itself that causes the greatest damage," Dr. Bose noted. "A lot of the harm comes from the body’s response to infection. If we can learn how to control that response, it could help us develop new treatments not only for RSV but for other serious respiratory and non-respiratory viral infections as well."

The collaboration with the Fox Chase Cancer Center is viewed by the academic community as a model for how land-grant universities can bridge the gap between basic laboratory science and translational clinical applications. By leveraging the specific strengths of both institutions, the researchers are positioned to address the "regulatory failure" of the immune system that characterizes not only RSV but potentially influenza, SARS-CoV-2, and other emerging respiratory threats.

The Path Forward: Therapeutic Development

As the project commences, the research team is set to utilize a combination of in vitro cell culture models and advanced animal models to visualize the inflammatory response in real-time. The ultimate goal is to identify a "therapeutic window"—a period during which a drug can inhibit the inflammatory signaling without preventing the immune system from successfully eradicating the virus.

Expected Milestones:

1. Year 1-2: Refinement of the signaling pathway map and identification of candidate small-molecule inhibitors.
2. Year 3-4: Pre-clinical efficacy testing to ensure that blocking these pathways does not result in an increase in viral load (a common concern in immunomodulatory therapy).
3. Year 5: Formulation of a roadmap for potential human clinical trials.

A Broader Impact

If successful, this research could fundamentally change how we manage viral pandemics. By focusing on the "host-directed" approach, clinicians could potentially stock-pile treatments that work against a class of viruses rather than just one specific strain. This would be a monumental shift in the face of future viral mutations and outbreaks, providing a safety net that protects the lung tissue from the very defense mechanisms intended to save it.

As the scientific community watches this project unfold, the focus remains on the delicate balance of the human immune system. For millions of people globally, the work happening in the labs at WSU and Fox Chase could eventually mean the difference between a mild, manageable infection and a life-altering respiratory crisis.

For more information on current research at the Washington State University College of Veterinary Medicine, please visit the official university news portal or the Department of Veterinary Microbiology and Pathology.